Cleveland Clinic | Strategic Alliance Partners

The Cleveland Clinic team's real-world findings presented at ESC 2026 are hypothesis-generating and need prospective confirmation but point to a low threshold for OSA screening.

Milind Desai, MD, MBA, explains the domino effect linking obesity, obstructive sleep apnea, and hypertrophic cardiomyopathy—and why treating obesity may break the chain.

Pharmacists’ medication expertise can mitigate GI adverse effects and improve outcomes for patients beginning obesity pharmacotherapy

Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES, FADCES, FCCP, explores the most significant advancements in continuous glucose monitoring (CGM) and automated insulin delivery in 2026.

Health systems coordinate pharmacy, payers, clinicians, labs, and electronic health record (EHR) teams to deliver ultra-high-cost gene therapies.

Early electronic health record (EHR) collaboration, scalable clinical infrastructure, and payer strategy planning are essential for pharmacists as cell and gene therapies expand across disease states.

Managing high-cost oncology therapies requires extensive cross-functional coordination, with pharmacists playing a central role.

Clinicians learn to optimize type 2 diabetes treatment using automated insulin delivery data, enhancing patient safety and education for effective management.

Diana Isaacs, PharmD, highlights evolving criteria for insulin pump therapy in type 2 diabetes.

Specialty pharmacy services are helping improve IBD care by supporting patient education, access, and confidence in biosimilars

Pharmacists play a vital role in preventing maternal and neonatal mortality by understanding pregnancy-specific medication needs and emergency care strategies.

Diana Isaacs, PharmD, discusses evolving perceptions of obesity, the expanding role of pharmacotherapy, and how pharmacists can drive access, counseling, and long-term metabolic health.